Consequently, targeting TRF2 in cancers could be a valuable multi-hit strategy via cell-autonomous and non-cell-autonomous processes by promoting senescence as well as impairing neo-angiogenesis and immune escape. This evidence concerns the gene TERF2 and cancer.